Have a personal or library account? Click to login
Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Cover

Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Global Heart
Volume 17 (2022): Issue 1
By: Mohamed Khalfallah,  Dina A. Maria and  Amany Allaithy  
Open Access
|Mar 2022

References

  1. 1Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. AACN Clin Issues. 2006; 17(1): 50–5. DOI: 10.1097/00044067-200601000-00007
    Back to article
  2. 2Wahab NN, Cowden EA, Pearce NJ, et al. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002; 40(10): 1748–1754. DOI: 10.1016/S0735-1097(02)02483-X
    Back to article
  3. 3Cid Álvarez B, Gude F, Cadarso Suárez C, et al. Admission and fasting plasma glucose for estimating risk of death of diabetic and nondiabetic patients with acute coronary syndrome: Nonlinearity of hazard ratios and time dependent comparison. Am Heart J. 2009; 158: 989–97. DOI: 10.1016/j.ahj.2009.10.004
    Back to article
  4. 4Zeller M, Steg P, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med. 2005; 165(10): 1192–1198. DOI: 10.1001/archinte.165.10.1192
    Back to article
  5. 5Gokhroo R, Mittal SR. Electrocardiographic correlates of hyperglycemia in acute myocardial infarction. Int J Cardiol. 1989; 22: 267–269. DOI: 10.1016/0167-5273(89)90078-8
    Back to article
  6. 6Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014; 11(11): 1185–200. DOI: 10.7150/ijms.10001
    Back to article
  7. 7Robinson LE, van Soeren MH. Insulin resistance and hyperglycemia in critical illness: Role of insulin in glycemic control. AACN Clin Issues. 2004; 15: 45–62. DOI: 10.1097/00044067-200401000-00004
    Back to article
  8. 8Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Crit CareMed. 2007; 35: S508–18. DOI: 10.1097/01.CCM.0000278047.06965.20
    Back to article
  9. 9De Luca G, Suryapranata H, Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: An overview of current status. Prog Cardiovasc Dis. 2008; 50: 352–82. DOI: 10.1016/j.pcad.2007.11.004
    Back to article
  10. 10Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016; 68: 539–51. DOI: 10.1016/j.ihj.2016.04.006
    Back to article
  11. 11Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012; 60(16): 1581–1598. DOI: 10.1016/j.jacc.2012.08.001
    Back to article
  12. 12American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2019. Diabetes Care. 2019 Jan; 42(Supplement 1): S13–S28. DOI: 10.2337/dc19-S002
    Back to article
  13. 13Marenzi G, Cosentino N, Milazzo V, et al. Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Acute Myocardial Infarction: A Prospective Study. Diabetes Care. 2018; 41: 847–53. DOI: 10.2337/dc17-1732
    Back to article
  14. 14Chu J, Tang J, Lai Y, et al. Association of stress hyperglycemia ratio with intracoronary thrombus burden in diabetic patients with ST-segment elevation myocardial infarction. J Thorac Dis. 2020 Nov; 12(11): 6598–6608. DOI: 10.21037/jtd-20-2111
    Back to article
  15. 15Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010; 22: 6B–14B.
    Back to article
  16. 16Kirma C, Izgi A, Dundar C, et al. Clinical and prodedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: Experience at a single center. Circ J. 2008; 72: 716–721. DOI: 10.1253/circj.72.716
    Back to article
  17. 17Karlsberg PP, Cryer PE, Roberts R. Serial plasma catecholamines response early in the course of clinical acutemyocardial infarction: Relation to infarct extent and mortality. Am. Heart J. 102(1981): 24–29. DOI: 10.1016/0002-8703(81)90408-7
    Back to article
  18. 18Petersen CL, Nielsen JR, Petersen BL, Kjaer A. Catecholaminergic activation in acute myocardial infarction: Time course and relation to left ventricular performance. Cardiology. 2003; 100: 23–8. DOI: 10.1159/000072388
    Back to article
  19. 19Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation. 2002 Oct 15; 106(16): 2067–72. DOI: 10.1161/01.CIR.0000034509.14906.AE
    Back to article
  20. 20Nakamura T, Ako J, Kadowaki T, et al. Impact of acute hyperglycemia during primary stent implantation in patients with ST-elevation myocardial infarction. J Cardiol. 2009 Apr; 53(2): 272–7. DOI: 10.1016/j.jjcc.2008.11.011
    Back to article
  21. 21Deckers JW, van Domburg RT, Akkerhuis M, Nauta ST. Relation of Admission Glucose Levels, Short- and Long-Term (20-Year) Mortality After Acute Myocardial Infarction. Am J Cardiol. 2013; 112(9): 1306–10. DOI: 10.1016/j.amjcard.2013.06.007
    Back to article
  22. 22Squire IB, Nelson CP, Ng LL, et al. Prognostic value of admission blood glucose concentration and diabetes diagnosis on survival after acute myocardial infarction; results from 4702 index cases in routine practice. Clin Sci. 2010; 118(8): 527–35. DOI: 10.1042/CS20090322
    Back to article
  23. 23Ishihara M, Kojima S, Sakamoto T, et al. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J. 2005; 150: 814–20. DOI: 10.1016/j.ahj.2004.12.020
    Back to article
  24. 24Timmer J, Hoekstra M, Nijsten M, et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with STsegment elevation myocardial infarction treated with percutaneous coronary intervention. Circulation. 2011; 124: 704–11. DOI: 10.1161/CIRCULATIONAHA.110.985911
    Back to article
  25. 25Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia. 1993; 36: 1119–1125. DOI: 10.1007/BF00401055
    Back to article
  26. 26Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus a reversible phenomenon. J Clin Invest. 1979; 63: 485–493. DOI: 10.1172/JCI109326
    Back to article
  27. 27Ceriello A, Giugliano D, Quatraro A, et al. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism. 1989; 38: 1162–1163. DOI: 10.1016/0026-0495(89)90152-2
    Back to article
  28. 28Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of the oxidative stress. Diabetes. 1995; 44: 924–928. DOI: 10.2337/diab.44.8.924
    Back to article
  29. 29Ceriello A, Giugliano D, Quatraro A, et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988; 31: 889–891. DOI: 10.1007/BF00265372
    Back to article
  30. 30Sakamoto T, Ogawa H, Kawano H, et al. Rapid change of platelet aggregability in acute hyperglycemia. Detection by a novel laser-light scattering method. Thromb Haemost. 2000; 83: 475–479. DOI: 10.1055/s-0037-1613839
    Back to article
  31. 31Khalfallah M, Elsheikh A. Incidence, predictors, and outcomes of new-onset atrial fibrillation in patients with ST-elevation myocardial infarction. Ann Noninvasive Electrocardiol. 2020 Jul; 25(4): e12746. Epub 2020 Jan 23. DOI: 10.1111/anec.12746
    Back to article
  32. 32Bolk J, van der Ploeg TJ, Cornel JH, et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001; 79: 207–14. DOI: 10.1016/S0167-5273(01)00422-3
    Back to article
  33. 33Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: Implications for patients with and without recognized diabetes. Circulation. 2005; 111: 3078–86. DOI: 10.1161/CIRCULATIONAHA.104.517839
    Back to article
  34. 34Planer D, Witzenbichler B, Guagliumi G, et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The HORIZONS-AMI trial. Int J Cardiol. 2013; 167(September 6): 2572–2579. DOI: 10.1016/j.ijcard.2012.06.054
    Back to article
  35. 35Kim EJ, Jeong MH, Kim JH, et al. Clinical impact of admission hyperglycemia on in-hospital mortality in acute myocardial infarction patients. Int J Cardiol. 2017; 236(1): 9–15. DOI: 10.1016/j.ijcard.2017.01.095
    Back to article
  36. 36Khalfallah M, Abdelmageed R, Allaithy A. Very Early Versus Early Percutaneous Coronary Intervention in Patients with Decreased e-GFR after Successful Fibrinolytic Therapy. Glob Heart. 2020 Apr 16; 15(1): 34. DOI: 10.5334/gh.794
    Back to article
  37. 37Reffelmann T, Kloner RA. The ‘no-reflow’ phenomenon: Basic science and clinical correlates. Heart. 2002; 87: 162–8. DOI: 10.1136/heart.87.2.162
    Back to article
  38. 38Khalfallah M, Elsheikh A, Abdalaal M. Very Early Versus Early Percutaneous Coronary Intervention After Successful Fibrinolytic Therapy in Pharmacoinvasive Strategy. Glob Heart. 2018 Dec; 13(4): 261–265. DOI: 10.1016/j.gheart.2018.06.003
    Back to article
  39. 39Galiuto L, Garramone B, Burzotta F, et al. Thrombus aspiration reduces microvascular obstruction after primary coronary intervention: A myocardial contrast echocardiography substudy of the REMEDIA Trial. J Am Coll Cardiol. 2006; 48: 1355–60. DOI: 10.1016/j.jacc.2006.05.059
    Back to article
  40. 40Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: The EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009; 53: 309–15. DOI: 10.1016/j.jacc.2008.10.017
    Back to article
  41. 41Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002; 122: 1322–32. DOI: 10.1378/chest.122.4.1322
    Back to article
  42. 42Ceriello A. Cardiovascular effects of acute hyperglycaemia: Pathophysiological underpinnings. Diab Vasc Dis Res. 2008; 5: 260–268. DOI: 10.3132/dvdr.2008.038
    Back to article
  43. 43Piconi L, Quagliaro L, Assaloni R, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006; 22: 198–203. DOI: 10.1002/dmrr.613
    Back to article
  44. 44Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: The role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003; 52: 2795–2804. DOI: 10.2337/diabetes.52.11.2795
    Back to article
  45. 45Khalfallah M, Abdalaal M, Adel M. Contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction: Is it affected by treatment strategy? Global Heart. 2019 Sep; 14(3): 295–302. DOI: 10.1016/j.gheart.2019.07.001
    Back to article
  46. 46Khalfallah M, Allaithy A, Maria DA. Incidence, predictors and outcomes of contrast-induced nephropathy in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Global Heart. 2021; 16(1): 57. DOI: 10.5334/gh.1071
    Back to article
  47. 47Marenzi G, De Metrio M, Rubino M, et al. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. Am Heart J. 2010 Dec; 160(6): 1170–7. DOI: 10.1016/j.ahj.2010.09.022
    Back to article
  48. 48Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep. 2008; 60(1): 119–126.
    Back to article
DOI: https://doi.org/10.5334/gh.1111 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Oct 19, 2021
Accepted on: Mar 9, 2022
Published on: Mar 29, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Impact,
stress hyperglycemia,
no-reflow phenomenon,
ST elevation myocardial infarction,
primary percutaneous coronary intervention

© 2022 Mohamed Khalfallah, Dina A. Maria, Amany Allaithy, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 17 (2022): Issue 1Next article